Noemı́ Reguart
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.2%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 99
- Lung Cancer Diagnosis and Treatment 26
- Oncology 72
- Lung Cancer Research Studies 24
- Cancer Immunotherapy and Biomarkers 21
- Colorectal Cancer Treatments and Studies 13
- Co-authors
- David M. Jablons (14 shared papers)Liang You (12 shared papers)Biao He (11 shared papers)Zhidong Xu (11 shared papers)Iwao Mikami (11 shared papers)R Cebolla Rosell (23 shared papers)Miquel Tarón (18 shared papers)Julien Mazières (9 shared papers)
- Journals
- Journal of Thoracic Oncology (25 papers)Lung Cancer (15 papers)Annals of Oncology (15 papers)Clinical Lung Cancer (6 papers)Cancer Treatment Reviews (6 papers)
- Partner nations
- SpainUnited StatesFrance
In The Last Decade
Noemı́ Reguart
187 papers receiving 16.1k citations
Noemı́ Reguart's Hit Papers
Peers
Comparison fields: 5 of 133
- Pulmonary and Respiratory Medicine 9.3k
- Oncology 7.2k
- Cancer Research 2.6k
- Molecular Biology 4.6k
- Pathology and Forensic Medicine 732
Countries citing papers authored by Noemı́ Reguart
This map shows the geographic impact of Noemı́ Reguart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noemı́ Reguart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noemı́ Reguart more than expected).
Fields of papers citing papers by Noemı́ Reguart
This network shows the impact of papers produced by Noemı́ Reguart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noemı́ Reguart. The network helps show where Noemı́ Reguart may publish in the future.
Co-authors
The 25 scholars most cited alongside Noemı́ Reguart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 192 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2012 | 4725 |
| 2 | Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer Hit paper breakdown → | 2009 | 1998 |
| 3 | Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 732 |
| 4 | Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ Hit paper breakdown → | 2021 | 409 |
| 5 | 2017 | 337 | |
| 6 | Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer Hit paper breakdown → | 2023 | 332 |
| 7 | 2006 | 320 | |
| 8 | 2011 | 270 | |
| 9 | 2010 | 269 | |
| 10 | 2004 | 236 | |
| 11 | 2004 | 225 | |
| 12 | Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study Hit paper breakdown → | 2023 | 223 |
| 13 | 2015 | 222 | |
| 14 | 2021 | 222 | |
| 15 | Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer Hit paper breakdown → | 2021 | 202 |
| 16 | 2017 | 192 | |
| 17 | 2005 | 191 | |
| 18 | 2004 | 174 | |
| 19 | 2017 | 167 | |
| 20 | 2018 | 167 |
About Noemı́ Reguart
Noemı́ Reguart is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Cell Biology, having authored 192 papers that have together received 16.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (99 papers), Lung Cancer Diagnosis and Treatment (26 papers), Lung Cancer Research Studies (24 papers), Cancer Genomics and Diagnostics (21 papers), Cancer Immunotherapy and Biomarkers (21 papers), Colorectal Cancer Treatments and Studies (13 papers), Wnt/β-catenin signaling in development and cancer (12 papers) and Cancer-related gene regulation (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (9.3k citations), Oncology (7.2k citations), Cancer Research (2.6k citations), Molecular Biology (4.6k citations) and Pathology and Forensic Medicine (732 citations). Noemı́ Reguart has collaborated with scholars based in Spain, United States and France. Frequent co-authors include David M. Jablons, Liang You, Biao He, Zhidong Xu, Iwao Mikami, R Cebolla Rosell, Miquel Tarón, Julien Mazières, Jordi Remón and Frank P. McCormick. Their work appears in journals such as Journal of Thoracic Oncology, Lung Cancer, Annals of Oncology, Clinical Lung Cancer and Cancer Treatment Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.